Heart valve engineering: Decellularized allograft matrices in clinical practice

Biomedizinische Technik

Volumn 58, Issue 5, 2013, Pages 453-456

  Neumann, Anneke ^a   Cebotari, Serghei ^a   Tudorache, Igor ^a   Haverich, Axel ^a   Sarikouch, Samir ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Allogenic; Artificial; Heart valve replacement; Matrices; Scaffolds; Tissue engineering

Indexed keywords

GRAFTS; MATRIX ALGEBRA; SCAFFOLDS; SCAFFOLDS (BIOLOGY); TISSUE; TISSUE ENGINEERING;

ALLOGENIC; ARTIFICIAL; CLINICAL EXPERIENCE; CLINICAL PRACTICES; CONGENITAL HEART DISEASE; HEART VALVE REPLACEMENT; PULMONARY VALVES; RIGHT VENTRICULAR;

HEART;

TISSUE SCAFFOLD;

ANIMAL; BIOPROSTHESIS; CELL FREE SYSTEM; EQUIPMENT; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; HUMAN; METHODOLOGY; PROSTHESIS; REVIEW; TISSUE ENGINEERING; VALVULAR HEART DISEASE; DEVICES; HEART VALVE DISEASES; PROCEDURES; TISSUE SCAFFOLD;

ANIMALS; BIOPROSTHESIS; CELL-FREE SYSTEM; HEART VALVE DISEASES; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; PROSTHESIS DESIGN; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84893119143     PISSN: 00135585     EISSN: None     Source Type: Journal    
DOI: 10.1515/bmt-2012-0115     Document Type: Review

References (39)

1. Baraki H, Tudorache I, Braun M, et al. Orthotopic replacement of the aortic valve with decellularized allograft in a sheep model. Biomaterials 2009; 30: 6240-6246.
2. Bechtel JF, Stierle U, Sievers HH. Fifty-two months' mean follow-up of decellularized SynerGraft-treated pulmonary valve allografts. J Heart Valve Dis 2008; 17: 98-104; discussion 104.
3. Brown JW, Elkins RC, Clarke DR, et al. Performance of the cryovalve SG human decellularized pulmonary valve in 342 patients relative to the conventional cryovalve at a mean follow-up of four years. J Thorac Cardiovasc Surg 2010; 139: 339-348.
4. Brown JW, Ruzmetov M, Eltayeb O, Rodefeld MD, Turrentine MW. Performance of SynerGraft decellularized pulmonary homograft in patients undergoing a ross procedure. Ann Thorac Surg 2011; 91: 416-422; discussion 422-413.
5. Burch PT, Kaza AK, Lambert LM, Holubkov R, Shaddy RE, Hawkins JA. Clinical performance of decellularized cryopreserved valved allografts compared with standard allografts in the right ventricular outflow tract. Ann Thorac Surg 2010; 90: 1301-1305; discussion 1306.
6. Cebotari S, Lichtenberg A, Tudorache I, et al. Clinical application of tissue engineered human heart valves using autologous progenitor cells. Circulation 2006; 114: I132-I137.
7. Cebotari S, Mertsching H, Kallenbach K, et al. Construction of autologous human heart valves based on an acellular allograft matrix. Circulation 2002; 106: I63-I68.
8. Cebotari S, Tudorache I, Ciubotaru A, et al. Use of fresh decellularized allografts for pulmonary valve replacement may reduce the reoperation rate in children and young adults: early report. Circulation 2011; 124: S115-S123.
9. Cebotari S, Tudorache I, Jaekel T, et al. Detergent decellularization of heart valves for tissue engineering: toxicological effects of residual detergents on human endothelial cells. Artif Organs 2010; 34: 206-210.
10. Cicha I, Ruffer A, Cesnjevar R, et al. Early obstruction of decellularized xenogenic valves in pediatric patients: involvement of inflammatory and fibroproliferative processes. Cardiovasc Pathol 2011; 20: 222-231.
11. Da Costa FD, Costa AC, Prestes R, et al. The early and midterm function of decellularized aortic valve allografts. Ann Thorac Surg 2010; 90: 1854-1860.
12. Da Costa FD, Dohmen PM, Duarte D, et al. Immunological and echocardiographic evaluation of decellularized versus cryopreserved allografts during the ross operation. Eur J Cardiothorac Surg 2005; 27: 572-578.
13. Da Costa FD, Santos LR, Collatusso C, et al. Thirteen years' experience with the ross operation. J Heart Valve Dis 2009; 18: 84-94.
14. Dijkman PE, Driessen-Mol A, Frese L, Hoerstrup SP, Baaijens FP. Decellularized homologous tissue-engineered heart valves as off-the-shelf alternatives to xeno-and homografts. Biomaterials 2012; 33: 4545-4554.
15. Dohmen PM, da Costa F, Yoshi S, et al. Histological evaluation of tissue-engineered heart valves implanted in the juvenile sheep model: is there a need for in-vitro seeding? J Heart Valve Dis 2006; 15: 823-829.
16. Emmert MY, Weber B, Wolint P, et al. Stem cell-based transcatheter aortic valve implantation: first experiences in a pre-clinical model. JACC Cardiovasc Interv 2012; 5: 874-883.
17. Gerson CJ, Elkins RC, Goldstein S, Heacox AE. Structural integrity of collagen and elastin in SynerGraft® decellularizedcryopreserved human heart valves. Cryobiology 2012; 64: 33-42.
18. Hoerstrup SP, Cummings Mrcs I, Lachat M, et al. Functional growth in tissue-engineered living, vascular grafts: follow-up at 100 weeks in a large animal model. Circulation 2006; 114: I159-I166.
19. Kasimir MT, Rieder E, Seebacher G, et al. Decellularization does not eliminate thrombogenicity and inflammatory stimulation in tissue-engineered porcine heart valves. J Heart Valve Dis 2006; 15: 278-286; discussion 286.
20. Kneib C, von Glehn CQ, Costa FD, Costa MT, Susin MF. Evaluation of humoral immune response to donor HLA after implantation of cellularized versus decellularized human heart valve allografts. Tissue Antigens 2012; 80: 165-174.
21. Konuma T, Devaney EJ, Bove EL, et al. Performance of cryovalve sg decellularized pulmonary allografts compared with standard cryopreserved allografts. Ann Thorac Surg 2009; 88: 849-854; discussion 554-845.
22. Lichtenberg A, Tudorache I, Cebotari S, et al. Preclinical testing of tissue-engineered heart valves re-endothelialized under simulated physiological conditions. Circulation 2006; 114: I559-I565.
23. Lutter G, Metzner A, Jahnke T, et al. Percutaneous tissueengineered pulmonary valved stent implantation. Ann Thorac Surg 2010; 89: 259-263.
24. Mendelson K, Schoen FJ. Heart valve tissue engineering: concepts, approaches, progress, and challenges. Ann Biomed Eng 2006; 34: 1799-1819.
25. Miller DV, Edwards WD, Zehr KJ. Endothelial and smooth muscle cell populations in a decellularized cryopreserved aortic homograft (SynerGraft) 2 years after implantation. J Thorac Cardiovasc Surg 2006; 132: 175-176.
26. Mulinari LA, Navarro FB, Pimentel GK, et al. The use and midium-term evaluation of decellularized allograft cusp in the surgical treatment of the tetralogy of fallot. Rev Bras Cir Cardiovasc 2008; 23: 197-203.
27. Narine K, Ing EC, Cornelissen M, et al. Readily available porcine aortic valve matrices for use in tissue valve engineering. Is cryopreservation an option? Cryobiology 2006; 53: 169-181.
28. Rieder E, Seebacher G, Kasimir MT, et al. Tissue engineering of heart valves: decellularized porcine and human valve scaffolds differ importantly in residual potential to attract monocytic cells. Circulation 2005; 111: 2792-2797.
29. Ruffer A, Purbojo A, Cicha I, et al. Early failure of xenogenous de-cellularised pulmonary valve conduits -a word of caution! Eur J Cardiothorac Surg 2010; 38: 78-85.
30. Ruzmetov M, Shah JJ, Geiss DM, Fortuna RS. Decellularized versus standard cryopreserved valve allografts for right ventricular outflow tract reconstruction: a single-institution comparison. J Thorac Cardiovasc Surg 2012; 143: 543-549.
31. Schmidt D, Dijkman PE, Driessen-Mol A, et al. Minimallyinvasive implantation of living tissue engineered heart valves: a comprehensive approach from autologous vascular cells to stem cells. J Am Coll Cardiol 2010; 56: 510-520.
32. Sharp MA, Phillips D, Roberts I, Hands L. A cautionary case: the SynerGraft vascular prosthesis. Eur J Vasc Endovasc Surg 2004; 27: 42-44.
33. Simon P, Kasimir MT, Seebacher G, et al. Early failure of the tissue engineered porcine heart valve SynerGraft in pediatric patients. Eur J Cardiothorac Surg 2003; 23: 1002-1006; discussion 1006.
34. Stock UA, Degenkolbe I, Attmann T, Schenke-Layland K, Freitag S, Lutter G. Prevention of device-related tissue damage during percutaneous deployment of tissueengineered heart valves. J Thorac Cardiovasc Surg 2006; 131: 1323-1330.
35. Tavakkol Z, Gelehrter S, Goldberg CS, Bove EL, Devaney EJ, Ohye RG. Superior durability of SynerGraft pulmonary allografts compared with standard cryopreserved allografts. Ann Thorac Surg 2005; 80: 1610-1614.
36. Tudorache I, Calistru A, Baraki H, et al. Orthotopic replacement of aortic heart valves with tissue engineered grafts. Tissue Eng A 2013 April 26 [Epub ahead of print].
37. Wollmann LC, Laurindo CA, Costa FD, Moreno AN. Effects of cryopreservation and/or decellularization on extracellular matrix of porcine valves. Rev Bras Cir Cardiovasc 2011; 26: 490-496.
38. Zehr KJ, Yagubyan M, Connolly HM, Nelson SM, Schaff HV. Aortic root replacement with a novel decellularized cryopreserved aortic homograft: postoperative immunoreactivity and early results. J Thorac Cardiovasc Surg 2005; 130: 1010-1015.
39. Zhou J, Fritze O, Schleicher M, et al. Impact of heart valve decellularization on 3-D ultrastructure, immunogenicity and thrombogenicity. Biomaterials 2010; 31: 2549-2554.